Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-120 or AG-221 plus azacitidine in newly diagnosed IDH-mutant acute myeloid leukemia
NL-OMON54569Phase 2Recruiting
- Sponsor
- Celgene Corporation
- Start
- Feb 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enasidenib, ivosidenib, azacitidine in acute myeloid leukemia (AML), sponsored by Celgene Corporation. Started Feb 2017; status: recruiting.
02
Drugs
enasidenibivosidenibazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON54569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54569.